Shares jump after the company releases upbeat clinical news.
News & Analysis: Denali Therapeutics Inc
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
Here's why shares of these drugmakers have a very slim chance to provide anything but losses.
Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.
Can either of these drugmakers bounce back from recent troubles.